Edoxaban vs. warfarin in patients with atrial fibrillation on amiodarone: a subgroup analysis of the ENGAGE AF-TIMI 48 trial.
暂无分享,去创建一个
A. Camm | H. Heidbuchel | D. Atar | E. Antman | R. Giugliano | E. Braunwald | S. Murphy | C. Ruff | J. Steffel
[1] R. Giugliano,et al. The P-glycoprotein transport system and cardiovascular drugs. , 2013, Journal of the American College of Cardiology.
[2] D. Atar,et al. Apixaban versus warfarin in patients with atrial fibrillation. , 2011, The New England journal of medicine.
[3] Massimo Santini,et al. Prognosis, disease progression, and treatment of atrial fibrillation patients during 1 year: follow-up of the Euro Heart Survey on atrial fibrillation. , 2008, European heart journal.
[4] S. Yusuf,et al. Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non‐valvular atrial fibrillation from the RE‐LY trial , 2011, Journal of thrombosis and haemostasis : JTH.
[5] A. Clemens,et al. Pharmacology, Pharmacokinetics, and Pharmacodynamics of Dabigatran Etexilate, an Oral Direct Thrombin Inhibitor , 2009, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.
[6] G. Hankey,et al. Dabigatran Etexilate: A New Oral Thrombin Inhibitor , 2011, Circulation.
[7] E. Antman,et al. Modelling and simulation of edoxaban exposure and response relationships in patients with atrial fibrillation , 2012, Thrombosis and Haemostasis.
[8] F. Lee,et al. Drug-Drug Interaction Studies of Cardiovascular Drugs Involving P-Glycoprotein, an Efflux Transporter, on the Pharmacokinetics of Edoxaban, an Oral Factor Xa Inhibitor , 2013, American Journal of Cardiovascular Drugs.
[9] E. Antman,et al. Edoxaban versus warfarin in patients with atrial fibrillation. , 2013, The New England journal of medicine.
[10] E. Braunwald,et al. Novel oral anticoagulants: focus on stroke prevention and treatment of venous thrombo-embolism. , 2011, European heart journal.
[11] J. Cairns. Stroke prevention in atrial fibrillation trial. , 1991, Circulation.
[12] Leon Poller,et al. Dabigatran versus warfarin in patients with atrial fibrillation. , 2009, The New England journal of medicine.
[13] E. Antman,et al. Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48). , 2010, American heart journal.
[14] E. Antman,et al. Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial , 2015, The Lancet.
[15] C. Ruff. Cardiology patient page: stroke prevention in atrial fibrillation. , 2012, Circulation.
[16] S. Schulman,et al. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non‐surgical patients , 2005, Journal of thrombosis and haemostasis : JTH.
[17] G. Breithardt,et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. , 2011, The New England journal of medicine.
[18] D Bergqvist,et al. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients , 2010, Journal of thrombosis and haemostasis : JTH.